
Progyny (PGNY) Stock Forecast & Price Target
Progyny (PGNY) Analyst Ratings
Bulls say
Progyny is supported by strong fundamentals, including Q3 revenue of $341.3M and EBITDA of $58.4M, both slightly ahead of consensus, while fertility revenue grew 11% Y/Y and pharmacy revenue rose 6% Y/Y. The company’s record 2027 selling season added 1.3M covered lives, with retention near 100%, more than 85 new clients expected, and over 3M lives slated for expanded product access, signaling durable demand and share gains across industries. Its attractive outlook is further reinforced by $57M of Q3 operating cash flow, aggressive share repurchases, and management’s repeated guidance raises, which together highlight a scalable business with strong cash generation and disciplined execution.
Bears say
Progyny is facing a fundamentally pressured outlook because its utilization-driven model can swing sharply quarter to quarter, making revenue visibility weak and leaving estimates vulnerable if attrition rises, utilization softens, or new solution revenue arrives more slowly than expected. Its growth is also tied to employment levels and employer benefit decisions, so an economic downturn or delayed customer adds could reduce membership, while a volatile political backdrop around reproductive rights may further dampen demand for its fertility services. Competitive intensity is worsening from traditional carriers and well-funded carve-out rivals, and operational risks in pharmacy supply and physician network quality could impair service delivery and contribute to the loss of large customers.
This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.
Progyny (PGNY) Analyst Forecast & Price Prediction
Start investing in Progyny (PGNY)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Progyny (PGNY) Forecast
Progyny (PGNY) Analyst Forecast & Price Prediction
Start investing in Progyny (PGNY)
Order type
Buy in
Order amount
Est. shares
0 shares